Dr Geoff Bellingan (UCL Clinical Physiology and medical director at University College London Hospitals)
A new treatment for patients with acute respiratory distress syndrome has seen mortality rates plummet by about 80 per cent. The results of a Phase II trial led by Dr Geoff Bellingan (UCL Clinical Physiology and medical director at University College London Hospitals) have been published in The Lancet Respiratory Medicine . Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are major causes of death in intensive care units. It is estimated that approximately 300-400,000 people suffer from ARDS in Western countries each year and the mortality rate remains high, around 35-45%, despite modern day care. At the moment there is no effective drug treatment for the syndrome, so patients tend to be treated with mechanical ventilation and optimisation and support of vital functions. Pulmonary vascular leakage occurs early in ALI/ARDS, and mortality remains high. An effective pharmacotherapy is desperately needed and Traumakine has been shown to reduce capillary leak.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
